US OptionsDetailed Quotes
PROK241220P5000
- 0.00
- 0.000.00%
15min DelayClose Dec 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-178.55%PremiumDec 20, 2024Expiry Date3.21Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.57Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ProKidney Stock Discussion
Sign in to post a comment
$ProKidney (PROK.US)$
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
1
1
$ProKidney (PROK.US)$ ProKidney | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Aaron Cowen(10.47%),Suvretta Capital Management, LLC(9.8%), etc.
SEC· 11 mins ago
SEC· 11 mins ago
$ProKidney (PROK.US)$ Today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA.
1
$ProKidney (PROK.US)$ Reuters· 2 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
2
$ProKidney (PROK.US)$ ProKidney Announces the Closing of $140 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
2
$ProKidney (PROK.US)$
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2
No comment yet
MARKET-TEST-DUMMY OP : 8% today not bad